BACKGROUND: Calcineurin inhibitor nephrotoxicity in nonrenal allograft recipients can lead to end-stage renal disease and the need for kidney transplantation. We sought to evaluate the role of alemtuzumab induction in this population. PATIENTS AND METHODS: We evaluated 144 patients undergoing kidney transplantation after nonrenal transplantation between May 18, 1998, and October 8, 2007. Seventy-two patients transplanted between January 15, 2003, and October 8, 2007, received alemtuzumab induction and continued their pretransplant immunosuppression. Seventy-two patients transplanted between May 18, 1998, and July 21, 2007, did not receive alemtuzumab induction, but received additional steroids and maintenance immunosuppression. Donor and recipient demographics were comparable. RESULTS: Overall, 1- and 3-year patient survival and renal function were comparable between the two groups. One- and 3-year graft survival was 93.0% and 75.3% in the alemtuzumab group and 83.3% and 68.7% in the no alemtuzumab group, respectively (P=0.051). The incidence of acute rejection was lower in the alemtuzumab group, 15.3%, than in the no alemtuzumab group, 41.7% (P=0.0001). The incidence of delayed graft function was lower in the alemtuzumab group, 9.7%, than in the no alemtuzumab group, 25.0% (P=0.003). The incidence of viral complications was comparable. CONCLUSION: Alemtuzumab induction with simple resumption of baseline immunosuppression in patients undergoing kidney transplantation after nonrenal transplantation represents a reasonable immunosuppressive strategy.
BACKGROUND:Calcineurin inhibitornephrotoxicity in nonrenal allograft recipients can lead to end-stage renal disease and the need for kidney transplantation. We sought to evaluate the role of alemtuzumab induction in this population. PATIENTS AND METHODS: We evaluated 144 patients undergoing kidney transplantation after nonrenal transplantation between May 18, 1998, and October 8, 2007. Seventy-two patients transplanted between January 15, 2003, and October 8, 2007, received alemtuzumab induction and continued their pretransplant immunosuppression. Seventy-two patients transplanted between May 18, 1998, and July 21, 2007, did not receive alemtuzumab induction, but received additional steroids and maintenance immunosuppression. Donor and recipient demographics were comparable. RESULTS: Overall, 1- and 3-year patient survival and renal function were comparable between the two groups. One- and 3-year graft survival was 93.0% and 75.3% in the alemtuzumab group and 83.3% and 68.7% in the no alemtuzumab group, respectively (P=0.051). The incidence of acute rejection was lower in the alemtuzumab group, 15.3%, than in the no alemtuzumab group, 41.7% (P=0.0001). The incidence of delayed graft function was lower in the alemtuzumab group, 9.7%, than in the no alemtuzumab group, 25.0% (P=0.003). The incidence of viral complications was comparable. CONCLUSION:Alemtuzumab induction with simple resumption of baseline immunosuppression in patients undergoing kidney transplantation after nonrenal transplantation represents a reasonable immunosuppressive strategy.
Authors: R Calne; P Friend; S Moffatt; A Bradley; G Hale; J Firth; J Bradley; K Smith; H Waldmann Journal: Lancet Date: 1998-06-06 Impact factor: 79.321
Authors: H P Tan; D J Kaczorowski; A Basu; M Unruh; J McCauley; C Wu; J Donaldson; I Dvorchik; L Kayler; A Marcos; P Randhawa; C Smetanka; T E Starzl; R Shapiro Journal: Am J Transplant Date: 2006-08-04 Impact factor: 8.086
Authors: Ron Shapiro; Amit Basu; Henkie Tan; Edward Gray; Akhtar Kahn; Parmjeet Randhawa; Noriko Murase; Adriana Zeevi; Alin Girnita; Diana Metes; Roberta Ness; Debra C Bass; Anthony J Demetris; John J Fung; Amadeo Marcos; Thomas E Starzl Journal: J Am Coll Surg Date: 2005-04 Impact factor: 6.113
Authors: Ron Shapiro; Demetrius Ellis; Henkie P Tan; Michael L Moritz; Amit Basu; Abhay N Vats; Akhtar S Khan; Edward A Gray; Adrianna Zeevi; Corde McFeaters; Gerri James; Mary Jo Grosso; Amadeo Marcos; Thomas E Starzl Journal: J Pediatr Date: 2006-06 Impact factor: 4.406
Authors: Bijan Eghtesad; John J Fung; Anthony J Demetris; Noriko Murase; Roberta Ness; Debra C Bass; Edward A Gray; Obaid Shakil; Bridget Flynn; Amadeo Marcos; Thomas E Starzl Journal: Liver Transpl Date: 2005-11 Impact factor: 5.799
Authors: Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson Journal: Transplantation Date: 2003-07-15 Impact factor: 4.939
Authors: Stuart J Knechtle; John D Pirsch; John H Fechner; Bryan N Becker; Andreas Friedl; Robert B Colvin; Lauralynn K Lebeck; L Thomas Chin; Yolanda T Becker; Jon S Odorico; Anthony M D'Alessandro; Munci Kalayoglu; Majed M Hamawy; Huaizhong Hu; Debra D Bloom; Hans W Sollinger Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Ron Shapiro; Adriana Zeevi; Amit Basu; Henkie P Tan; Liise K Kayler; Deanna M Blisard; Ngoc L Thai; Alin L Girnita; Parmjeet S Randhawa; Edward A Gray; Amadeo Marcos; Thomas E Starzl Journal: Transplantation Date: 2008-04-27 Impact factor: 4.939
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle Journal: Transplant Rev (Orlando) Date: 2019-04-05 Impact factor: 3.943
Authors: Hoa Le Mai; Michèle Treilhaud; Shani Leviatan Ben-Arye; Hai Yu; Hélène Perreault; Evelyn Ang; Katy Trébern-Launay; Julie Laurent; Stéphanie Malard-Castagnet; Anne Cesbron; Thi Van Ha Nguyen; Sophie Brouard; Lionel Rostaing; Pauline Houssel-Debry; Christophe Legendre; Sophie Girerd; Michèle Kessler; Emmanuel Morelon; Antoine Sicard; Valérie Garrigue; Georges Karam; Xi Chen; Magali Giral; Vered Padler-Karavani; Jean Paul Soulillou Journal: Transplant Direct Date: 2018-03-20